Tricuspid Valve Interventions

Edited by

Francesco Maisano, MD, FESC, FHFAHead of Cardiac Surgery and Director of the Valve Center, IRCCS San Raffaele Hospital, Milan, Italy

Fabien Praz, MDInterventional Cardiologist and Associate Professor, Bern University Hospital, Switzerland

Marianna Adamo, MD, PhDInterventional Cardiologist, Heart Failure Physician, and Associate Professor, University of Brescia, Italy

Roberto M. Lang, MD, FASEFormerly Director of the Cardiac Noninvasive Imaging Laboratory and the A.J. Carlson Professor of Medicine, University of Chicago, Chicago, IL, USA

Yoshinobu Onuma, MD, PhDProfessor in Interventional Cardiology Medical Director, CORRIB Core Laboratory, University of Galway, Ireland

Tsung-Ying Tsai, MD, PhDClinical Scientist, Boston Scientific, Galway, Ireland

Martin B. Leon, MDDirector of the Center for Interventional Vascular Therapy, New York-Presbyterian/ Columbia University Irving Medical Center, New York, NY, USA

Patrick W. Serruys, MD, PhD, eFESC, FACCEstablished Professor of Interventional Medicine and Innovation, NUI Galway Senior Consultant, CORRIB Research Centre for Advanced Imaging and Core Laboratory College of Medicine, Nursing and Health Sciences, University of Galway, Ireland

Associate Editors

Pruthvi T.C. Revaiah, MD, DM, PhDCHIP Fellow at Icahn School of Medicine at Mount Sinai, New York, NY, USA

Aishwarya GuravResearch Assistant, University of Galway, Ireland

Tricuspid Valve Regurgitation is a common valvular pathology, estimated to affect 1.6 million people in the US alone. Even though guidelines recommend either medical therapy or surgical treatment, the misconception of the disorder as a benign disease (along with the high mortality rates of surgical intervention) has led to undertreatment of this disease and description of it as a “forgotten” valve. This text from international experts looks at the disease and the developing transcatheter interventions with
promising potential for use in the clinical setting.